Haploidentical Hematopoietic SCT May Be Superior to Conventional Consolidation/Maintenance Chemotherapy as Post-Remission Therapy for High-Risk Adult ALL

Bone Marrow Transplantation - United Kingdom
doi 10.1038/bmt.2014.195
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

High-Dose Chemotherapy With Autologous PDSCT as Post-Remission Therapy for AML

Bone Marrow Transplantation
TransplantationHematology
2001English

Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients With Intermediate-Risk Acute Myelogenous Leukemia in First Complete Remission

Clinical Cancer Research
Cancer ResearchOncology
2018English

Post-Remission Therapy of Adult Acute Myeloid Leukemia: High Dose Cytosine-Arabinoside Versus Other Consolidation Regimens

Medicinski Pregled
Medicine
2014English

A Randomized Trial of High-Versus Conventional-Dose Cytarabine in Consolidation Chemotherapy for Adult De Novo Acute Myeloid Leukemia in First Remission After Induction Therapy Containing High-Dose Cytarabine

Blood
BiochemistryImmunologyCell BiologyHematology
2005English

Good Outcome of Haploidentical Hematopoietic SCT as a Salvage Therapy in Children and Adolescents With Acquired Severe Aplastic Anemia

Bone Marrow Transplantation
TransplantationHematology
2014English

Risk Seekers May Be Antisocial After All

Clinical and Experimental Medical Sciences
2014English

Status of Minimal Residual Disease Determines Outcome of Autologous Hematopoietic SCT in Adult ALL

Bone Marrow Transplantation
TransplantationHematology
2009English

Consolidation Treatment for High Risk Solid Tumors in Children With Myeloablative Chemotherapy and Autologous Hematopoietic Progenitor Stem Cell Transplantation

Revista Brasileira de Hematologia e Hemoterapia
2013English

Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial

Journal of Cancer
Oncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy